# Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris

> **NCT01474798** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 11 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** RA-18C3

## Key facts

- **NCT ID:** NCT01474798
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-29
- **Primary completion:** 2012-10-31
- **Final completion:** 2012-12-31
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01474798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01474798, "Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01474798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*